76 related articles for article (PubMed ID: 22787836)
1. [Disability Assessment for Dementia (DAD), Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)].
Iijima S
Nihon Rinsho; 2011 Oct; 69 Suppl 8():471-4. PubMed ID: 22787836
[No Abstract] [Full Text] [Related]
2. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
3. Functional disability in Alzheimer disease: a validation study of the Brazilian version of the Disability Assessment for Dementia (DAD-Br).
Bahia VS; Carthery-Goulart MT; Novelli MM; Kato-Narita EM; Areza-Fegyveres R; Caramelli P; Nitrini R
Alzheimer Dis Assoc Disord; 2010; 24(3):291-5. PubMed ID: 20473140
[TBL] [Abstract][Full Text] [Related]
4. [DEX and executive dysfunction in activities of daily living in Alzheimer's disease and frontotemporal dementia].
Piquard A; Derouesné C; Meininger V; Lacomblez L
Psychol Neuropsychiatr Vieil; 2010 Sep; 8(3):215-24; quiz 225-7. PubMed ID: 20739260
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychological screening performance and the association with activities of daily living and instrumental activities of daily living in dementia: baseline and 18- to 24-month follow-up.
Monaci L; Morris RG
Int J Geriatr Psychiatry; 2012 Feb; 27(2):197-204. PubMed ID: 22223145
[TBL] [Abstract][Full Text] [Related]
6. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
7. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
8. Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues.
Perneczky R; Pohl C; Sorg C; Hartmann J; Komossa K; Alexopoulos P; Wagenpfeil S; Kurz A
Age Ageing; 2006 May; 35(3):240-5. PubMed ID: 16513677
[TBL] [Abstract][Full Text] [Related]
9. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
Gustavsson A; Cattelin F; Jönsson L
Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
[TBL] [Abstract][Full Text] [Related]
10. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
[TBL] [Abstract][Full Text] [Related]
11. [Planning and activities of daily living in Alzheimer's disease and frontotemporal dementia].
Piquard A; Derouesné C; Lacomblez L; Siéroff E
Psychol Neuropsychiatr Vieil; 2004 Jun; 2(2):147-56. PubMed ID: 15683978
[TBL] [Abstract][Full Text] [Related]
12. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
[TBL] [Abstract][Full Text] [Related]
13. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
[TBL] [Abstract][Full Text] [Related]
15. Functional disability in early Alzheimer's disease - a validation study of the Italian version of the disability assessment for dementia scale.
De Vreese LP; Caffarra P; Savarè R; Cerutti R; Franceschi M; Grossi E;
Dement Geriatr Cogn Disord; 2008; 25(2):186-94. PubMed ID: 18196940
[TBL] [Abstract][Full Text] [Related]
16. Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome.
Perneczky R; Pohl C; Sorg C; Hartmann J; Tosic N; Grimmer T; Heitele S; Kurz A
Int J Geriatr Psychiatry; 2006 Feb; 21(2):158-62. PubMed ID: 16416470
[TBL] [Abstract][Full Text] [Related]
17. Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living.
Yoon JS; Kim JM; Lee H; Shin IS; Choi SK
Hum Psychopharmacol; 2003 Dec; 18(8):627-33. PubMed ID: 14696022
[TBL] [Abstract][Full Text] [Related]
18. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.
Gauthier S; Ferris S
Int J Clin Pract Suppl; 2001 May; (120):29-39. PubMed ID: 11406924
[TBL] [Abstract][Full Text] [Related]
19. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
